Innovation in the Delivery of Behavioral Health Services

Literature Cited

1. 1.

   Adams JW, Savinkina A, Fox A, Behrends CN, Madushani RWMA, et al. 2022.. Modeling the cost-effectiveness and impact on fatal overdose and initiation of buprenorphine-naloxone treatment at syringe service programs. . Addiction 117:(10):2635–48
   [Crossref] [Google Scholar]
2. 2.

   Adeniran E, Quinn M, Wallace R, Walden RR, Labisi T, et al. 2023.. A scoping review of barriers and facilitators to the integration of substance use treatment services into US mainstream health care. . Drug Alcohol Depend. Rep. 7::100152
   [Crossref] [Google Scholar]
3. 3.

   Adner R. 2013.. The Wide Lens: What Successful Innovators See That Others Miss. New York:: Portfolio/Penguin
4. 4.

   Alegría M, Frank RG, Hansen HB, Sharfstein JM, Shim RS, Tierney M. 2021.. Transforming mental health and addiction services: Commentary describes steps to improve outcomes for people with mental illness and addiction in the United States. . Health Aff. 40:(2):226–34
   [Crossref] [Google Scholar]
5. 5.

   Allen JD, Towne SD Jr., Maxwell AE, DiMartino L, Leyva B, et al. 2017.. Measures of organizational characteristics associated with adoption and/or implementation of innovations: a systematic review. . BMC Health Serv. Res. 17::591
   [Crossref] [Google Scholar]
6. 6.

   Andrilla CHA, Patterson DG. 2022.. Tracking the geographic distribution and growth of clinicians with a DEA waiver to prescribe buprenorphine to treat opioid use disorder. . J. Rural Health 38:(1):87–92
   [Crossref] [Google Scholar]
7. 7.

   APHA (Am. Public Health Assoc.). 2009.. Support for community health workers to increase health access and to reduce health inequities. Statem. Policy 20091 , APHA, Washington, DC.: https://www.apha.org/policies-and-advocacy/public-health-policy-statements/policy-database/2014/07/09/14/19/support-for-community-health-workers-to-increase-health-access-and-to-reduce-health-inequities
8. 8.

   Archer J, Bower P, Gilbody S, Lovell K, Richards D, et al. 2012.. Collaborative care for depression and anxiety problems. . Cochrane Database Syst. Rev. 10::CD006525
   [Google Scholar]
9. 9.

   Aronowitz SV, Engel-Rebitzer E, Dolan A, Oyekanmi K, Mandell D, et al. 2021.. Telehealth for opioid use disorder treatment in low-barrier clinic settings: an exploration of clinician and staff perspectives. . Harm. Reduct. J. 18::119
   [Crossref] [Google Scholar]
10. 10.

    Bachhuber MA, Thompson C, Prybylowski A, Benitez JM, Mazzella SM, Barclay D. 2018.. Description and outcomes of a buprenorphine maintenance treatment program integrated within Prevention Point Philadelphia, an urban syringe exchange program. . Subst. Abuse 39:(2):167–72
    [Crossref] [Google Scholar]
11. 11.

    Bakker JP, Goldsack JC, Clarke M, Coravos A, Geoghegan C, et al. 2019.. A systematic review of feasibility studies promoting the use of mobile technologies in clinical research. . npj Digit. Med. 2::47
    [Crossref] [Google Scholar]
12. 12.

    Bao Y, McGuire TG, Chan Y-F, Eggman AA, Ryan AM, et al. 2017.. Value-based payment in implementing evidence-based care: the Mental Health Integration Program in Washington State. . Am. J. Manag. Care 23:(1):48–53
    [Google Scholar]
13. 13.

    Barnett ML, Gonzalez A, Miranda J, Chavira DA, Lau AS. 2018.. Mobilizing community health workers to address mental health disparities for underserved populations: a systematic review. . Adm. Policy Ment. Health 45:(2):195–211
    [Crossref] [Google Scholar]
14. 14.

    Barsky BA, Mehrotra A, Huskamp HA. 2023.. State policies could impede new efforts to increase access to medications for opioid use disorder. . JAMA Health Forum 4:(3):e230071
    [Crossref] [Google Scholar]
15. 15.

    Bates AE, Martin-Misener R. 2022.. Facilitators and barriers to nurse practitioners prescribing methadone for opioid use disorder in Nova Scotia: a qualitative study. . Can. J. Nurs. Res. 54:(1):15–26
    [Crossref] [Google Scholar]
16. 16.

    Bauer MS, Weaver K, Kim B, Miller C, Lew R, et al. 2019.. The Collaborative Chronic Care model for mental health conditions: from evidence synthesis to policy impact to scale-up and spread. . Med. Care 57:(10 Suppl. 3):S221–27
    [Crossref] [Google Scholar]
17. 17.

    Beer M. 2021.. Reflections: towards a normative and actionable theory of planned organizational change and development. . J. Change Manag. 21:(1):14–29
    [Crossref] [Google Scholar]
18. 18.

    Behrends CN, Lu X, Corry GJ, LaKosky P, Prohaska SM, et al. 2022.. Harm reduction and health services provided by syringe services programs in 2019 and subsequent impact of COVID-19 on services in 2020. . Drug Alcohol Depend. 232::109323
    [Crossref] [Google Scholar]
19. 19.

    Birken SA, Bunger AC, Powell BJ, Turner K, Clary AS, et al. 2017.. Organizational theory for dissemination and implementation research. . Implement. Sci. 12::62
    [Crossref] [Google Scholar]
20. 20.

    Birken SA, Haines ER, Hwang S, Chambers DA, Bunger AC, Nilsen P. 2020.. Advancing understanding and identifying strategies for sustaining evidence-based practices: a review of reviews. . Implement. Sci. 15::88
    [Crossref] [Google Scholar]
21. 21.

    Birken SA, Powell BJ, Presseau J, Kirk MA, Lorencatto F, et al. 2017.. Combined use of the Consolidated Framework for Implementation Research (CFIR) and the Theoretical Domains Framework (TDF): a systematic review. . Implement. Sci. 12::2
    [Crossref] [Google Scholar]
22. 22.

    Brackett CD, Duncan M, Wagner JF, Fineberg L, Kraft S. 2022.. Multidisciplinary treatment of opioid use disorder in primary care using the collaborative care model. . Subst. Abuse 43:(1):240–44
    [Crossref] [Google Scholar]
23. 23.

    Broffman L, D'Aunno T, Chang JE. 2023.. Factors associated with the adoption of evidence-based innovations by substance use disorder treatment organizations: a study of HIV testing. . J. Subst. Abuse Treat. 144::108929
    [Crossref] [Google Scholar]
24. 24.

    Brooklyn JR, Sigmon SC. 2017.. Vermont hub-and-spoke model of care for opioid use disorder: development, implementation, and impact. . J. Addict. Med. 11:(4):286–92
    [Crossref] [Google Scholar]
25. 25.

    Busch SH, Fiellin DA, Chawarski MC, Owens PH, Pantalon MV, et al. 2017.. Cost-effectiveness of emergency department–initiated treatment for opioid dependence. . Addiction 112:(11):2002–10
    [Crossref] [Google Scholar]
26. 26.

    Caldwell LL, Smith EA, Collins LM, Graham JW, Lai M, et al. 2012.. Translational research in South Africa: evaluating implementation quality using a factorial design. . Child Youth Care Forum 41:(2):119–36
    [Crossref] [Google Scholar]
27. 27.

    Carpenter SM, Menictas M, Nahum-Shani I, Wetter DW, Murphy SA. 2020.. Developments in mobile health just-in-time adaptive interventions for addiction science. . Curr. Addict. Rep. 7:(3):280–90
    [Crossref] [Google Scholar]
28. 28.

    Carreiro S, Newcomb M, Leach R, Ostrowski S, Boudreaux ED, Amante D. 2020.. Current reporting of usability and impact of mHealth interventions for substance use disorder: a systematic review. . Drug Alcohol Depend. 215::108201
    [Crossref] [Google Scholar]
29. 29.

    Carter J, Zevin B, Lum PJ. 2019.. Low barrier buprenorphine treatment for persons experiencing homelessness and injecting heroin in San Francisco. . Addict. Sci. Clin. Pract. 14::20
    [Crossref] [Google Scholar]
30. 30.

    Cattel D, Eijkenaar F. 2020.. Value-based provider payment initiatives combining global payments with explicit quality incentives: a systematic review. . Med. Care Res. Rev. 77:(6):511–37
    [Crossref] [Google Scholar]
31. 31.

    Caulkins JP, Gould A, Pardo B, Reuter P, Stein BD. 2021.. Opioids and the criminal justice system: new challenges posed by the modern opioid epidemic. . Annu. Rev. Criminol. 4::353–75
    [Crossref] [Google Scholar]
32. 32.

    CDC (Cent. Dis. Control Prev.). 2021.. Quarterly provisional drug overdose estimates with demographics (August). Stat., Natl. Cent. Health Stat., Washington, DC.: https://www.cdc.gov/nchs/nvss/vsrr/provisional-drug-overdose.htm
    [Google Scholar]
33. 33.

    Cerdá M, Krawczyk N, Hamilton L, Rudolph KE, Friedman SR, Keyes KM. 2021.. A critical review of the social and behavioral contributions to the overdose epidemic. . Annu. Rev. Public Health 42::95–114
    [Crossref] [Google Scholar]
34. 34.

    Chua KP, Dahlem CHY, Nguyen TD, Brummett CM, Conti RM, et al. 2022.. Naloxone and buprenorphine prescribing following US emergency department visits for suspected opioid overdose: August 2019 to April 2021. . Ann. Emerg. Med. 79:(3):225–36
    [Crossref] [Google Scholar]
35. 35.

    Coleman K, Austin BT, Brach C, Wagner EH. 2009.. Evidence on the Chronic Care Model in the new millennium. . Health Aff. 28:(1):75–85
    [Crossref] [Google Scholar]
36. 36.

    Côté-Boileau E, Denis J-L, Callery B, Sabean M. 2019.. The unpredictable journeys of spreading, sustaining and scaling healthcare innovations: a scoping review. . Health Res. Policy Syst. 17::84
    [Crossref] [Google Scholar]
37. 37.

    Dawson R, Lavori PW. 2008.. Sequential causal inference: application to randomized trials of adaptive treatment strategies. . Stat. Med. 27:(10):1626–45
    [Crossref] [Google Scholar]
38. 38.

    Dieperink J, DePaepe C. 2019.. Nurse practitioners: improving patient outcomes for opioid use disorder. . J. Nurse Pract. 15:(9):A12–14
    [Google Scholar]
39. 39.

    D'Onofrio G, O'Connor PG, Pantalon MV, Chawarski MC, Busch SH, et al. 2015.. Emergency department–initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. . JAMA 313:(16):1636–44
    [Crossref] [Google Scholar]
40. 40.

    Drug Enforc. Agency. 2021.. DEA finalizes measures to expand medication-assisted treatment. Press Release, June 28. https://www.dea.gov/press-releases/2021/06/28/dea-finalizes-measures-expand-medication-assisted-treatment
41. 41.

    Eddie D, Hoffman L, Vilsaint C, Abry A, Bergman B, et al. 2019.. Lived experience in new models of care for substance use disorder: a systematic review of peer recovery support services and recovery coaching. . Front. Psychol. 10::1052
    [Crossref] [Google Scholar]
42. 42.

    Fils-Aimé JR, Grelotti DJ, Thérosmé T, Kaiser BN, Raviola G, et al. 2018.. A mobile clinic approach to the delivery of community-based mental health services in rural Haiti. . PLOS ONE 13:(6):e0199313
    [Crossref] [Google Scholar]
43. 43.

    Frank RG, Humphreys K, Pollack H. 2021.. Our other epidemic: addiction. . JAMA Health Forum 2:(3):e210273
    [Crossref] [Google Scholar]
44. 44.

    Frank RG, Humphreys KN, Pollack HA. 2021.. Policy responses to the addiction crisis. . J. Health Politics Policy Law 46:(4):585–97
    [Crossref] [Google Scholar]
45. 45.

    Garattini L, Badinella Martini M, Nobili A. 2022.. Integrated care in Europe: time to get it together?. Appl. Health Econ. Health Policy 20:(2):145–47
    [Crossref] [Google Scholar]
46. 46.

    Gaveras G. 2023.. DEA telehealth proposal brings risks, not patient protections. . Health Affairs Forefront Blog, March 23. https://doi.org/10.1377/forefront.20230321.786321
    [Crossref] [Google Scholar]
47. 47.

    Goldman ML, Scharf DM, Brown JD, Scholle SH, Pincus HA. 2022.. Structural components of integrated behavioral health care: a comparison of national programs. . Psychiatr. Serv. 73:(5):584–87
    [Crossref] [Google Scholar]
48. 48.

    Granstrand O, Holgersson M. 2020.. Innovation ecosystems: a conceptual review and a new definition. . Technovation 90/91::102098
    [Crossref] [Google Scholar]
49. 49.

    Green TC, Clarke J, Brinkley-Rubinstein L, Marshall BDL, Alexander-Scott N, et al. 2018.. Postincarceration fatal overdoses after implementing medications for addiction treatment in a statewide correctional system. . JAMA Psychiatry 75:(4):405–7
    [Crossref] [Google Scholar]
50. 50.

    Greenhalgh T, Robert G, Macfarlane F, Bate P, Kyriakidou O. 2004.. Diffusion of innovations in service organizations: systematic review and recommendations. . Milbank Q. 82:(4):581–629
    [Crossref] [Google Scholar]
51. 51.

    Guastaferro K, Collins LM. 2021.. Optimization methods and implementation science: an opportunity for behavioral and biobehavioral interventions. . Implement. Res. Pract. 2::26334895211054363
    [Google Scholar]
52. 52.

    Gwadz MV, Collins LM, Cleland CM, Leonard NR, Wilton L, et al. 2017.. Using the multiphase optimization strategy (MOST) to optimize an HIV care continuum intervention for vulnerable populations: a study protocol. . BMC Public Health 17::383
    [Crossref] [Google Scholar]
53. 53.

    Hawk K, Hoppe J, Ketcham E, LaPietra A, Moulin A, et al. 2021.. Consensus recommendations on the treatment of opioid use disorder in the emergency department. . Ann. Emerg. Med. 78:(3):434–42
    [Crossref] [Google Scholar]
54. 54.

    Hedrich D, Alves P, Farrell M, Stöver H, Møller L, Mayet S. 2012.. The effectiveness of opioid maintenance treatment in prison settings: a systematic review. . Addiction 107:(3):501–17
    [Crossref] [Google Scholar]
55. 55.

    Hilty DM, Torous J, Parish MB, Chan SR, Xiong G, et al. 2021.. A literature review comparing clinicians’ approaches and skills to in-person, synchronous, and asynchronous care: moving toward competencies to ensure quality care. . Telemed. e-Health 27:(4):356–73
    [Crossref] [Google Scholar]
56. 56.

    Hood JE, Banta-Green CJ, Duchin JS, Breuner J, Dell W, et al. 2020.. Engaging an unstably housed population with low-barrier buprenorphine treatment at a syringe services program: lessons learned from Seattle, Washington. . Subst. Abuse 41:(3):356–64
    [Crossref] [Google Scholar]
57. 57.

    Jakubowski A, Rath C, Harocopos A, Wright M, Welch A, et al. 2021.. Implementation of buprenorphine services in NYC syringe services programs: a qualitative process evaluation. . Harm Reduct. J. 19::75
    [Crossref] [Google Scholar]
58. 58.

    Jones J, Tierney M, Jacobs G, Chien S-Y, Mallisham S. 2020.. Empowering psychiatric mental health nurse practitioners to expand treatment opportunities for veterans with opioid use disorder. . J. Addict. Nurs. 31:(4):261–68
    [Crossref] [Google Scholar]
59. 59.

    Jurecka CA, Barocas JA. 2023.. Using evidence to inform legislation aimed at curbing fentanyl deaths. . JAMA Health Forum 4:(1):e225202
    [Crossref] [Google Scholar]
60. 60.

    Katon W, Unützer J, Wells K, Jones L. 2010.. Collaborative depression care: history, evolution and ways to enhance dissemination and sustainability. . Gen. Hosp. Psychiatry 32:(5):456–64
    [Crossref] [Google Scholar]
61. 61.

    Keynejad RC, Dua T, Barbui C, Thornicroft G. 2018.. WHO Mental Health Gap Action Programme (mhGAP) intervention guide: a systematic review of evidence from low and middle-income countries. . Evid.-Based Ment. Health 21:(1):30–34
    [Crossref] [Google Scholar]
62. 62.

    Kilbourne AM, Beck K, Spaeth-Rublee B, Ramanuj P, O'Brien RW, et al. 2018.. Measuring and improving the quality of mental health care: a global perspective. . World Psychiatry 17:(1):30–38
    [Crossref] [Google Scholar]
63. 63.

    Kinoshita S, Cortright K, Crawford A, Mizuno Y, Yoshida K, et al. 2022.. Changes in telepsychiatry regulations during the COVID-19 pandemic: 17 countries and regions’ approaches to an evolving healthcare landscape. . Psychol. Med. 52:(13):2606–13
    [Crossref] [Google Scholar]
64. 64.

    Kleinman MB, Doran K, Felton JW, Satinsky EN, Dean D, et al. 2021.. Implementing a peer recovery coach model to reach low-income, minority individuals not engaged in substance use treatment. . Subst. Abuse 42:(4):726–34
    [Crossref] [Google Scholar]
65. 65.

    Kleinman MB, Felton JW, Johnson A, Magidson JF. 2021.. “I have to be around people that are doing what I'm doing”: the importance of expanding the peer recovery coach role in treatment of opioid use disorder in the face of COVID-19 health disparities. . J. Subst. Abuse Treat. 122::108182
    [Crossref] [Google Scholar]
66. 66.

    Kola L. 2020.. Global mental health and COVID-19. . Lancet Psychiatry 7:(8):655–57
    [Crossref] [Google Scholar]
67. 67.

    Komaromy M, Duhigg D, Metcalf A, Carlson C, Kalishman S, et al. 2016.. Project ECHO (Extension for Community Healthcare Outcomes): a new model for educating primary care providers about treatment of substance use disorders. . Subst. Abuse 37:(1):20–24
    [Crossref] [Google Scholar]
68. 68.

    Korthuis PT, McCarty D, Weimer M, Bougatsos C, Blazina I, et al. 2017.. Primary care–based models for the treatment of opioid use disorder: a scoping review. . Ann. Intern. Med. 166:(4):268–78
    [Crossref] [Google Scholar]
69. 69.

    Krawczyk N, Buresh M, Gordon MS, Blue TR, Fingerhood MI, Agus D. 2019.. Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: addressing a critical care gap. . J. Subst. Abuse Treat. 103::1–8
    [Crossref] [Google Scholar]
70. 70.

    Landis RK, Levin JS, Saloner B, Gordon AJ, Dick AW, et al. 2022.. Sociodemographic differences in quality of treatment to Medicaid enrollees receiving buprenorphine. . Subst. Abuse 43:(1):1057–71
    [Crossref] [Google Scholar]
71. 71.

    Lanham HJ, Papac J, Olmos DI, Heydemann EL, Simonetti N, et al. 2022.. Survey of barriers and facilitators to prescribing buprenorphine and clinician perceptions on the Drug Addiction Treatment Act of 2000 waiver. . JAMA Netw. Open 5:(5):e2212419
    [Crossref] [Google Scholar]
72. 72.

    Laricchia F. 2023.. Number of connected wearable devices worldwide from 2019 to 2022. . Statista, May 15. https://www.statista.com/statistics/487291/global-connected-wearabledevices/2019
    [Google Scholar]
73. 73.

    Leeman J, Birken SA, Powell BJ, Rohweder C, Shea CM. 2017.. Beyond “implementation strategies”: classifying the full range of strategies used in implementation science and practice. . Implement. Sci. 12::125
    [Crossref] [Google Scholar]
74. 74.

    Lei H, Nahum-Shani I, Lynch K, Oslin D, Murphy SA. 2012.. A “SMART” design for building individualized treatment sequences. . Annu. Rev. Clin. Psychol. 8::21–48
    [Crossref] [Google Scholar]
75. 75.

    Lim S, Cherian T, Katyal M, Goldfeld KS, McDonald R, et al. 2023.. Association between jail-based methadone or buprenorphine treatment for opioid use disorder and overdose mortality after release from New York City jails 2011–17. . Addiction 118:(3):459–67
    [Crossref] [Google Scholar]
76. 76.

    Lin LA, Casteel D, Shigekawa E, Weyrich MS, Roby DH, McMenamin SB. 2019.. Telemedicine-delivered treatment interventions for substance use disorders: a systematic review. . J. Subst. Abuse Treat. 101::38–49
    [Crossref] [Google Scholar]
77. 77.

    Lofwall MR, Walsh SL. 2014.. A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world. . J. Addict. Med. 8:(5):315–26
    [Crossref] [Google Scholar]
78. 78.

    Lowenstein M, Perrone J, Xiong RA, Snider CK, O'Donnell N, et al. 2022.. Sustained implementation of a multicomponent strategy to increase emergency department–initiated interventions for opioid use disorder. . Ann. Emerg. Med. 79:(3):237–48
    [Crossref] [Google Scholar]
79. 79.

    Miller CK. 2019.. Adaptive intervention designs to promote behavioral change in adults: What is the evidence?. Curr. Diabetes Rep. 19:(2):7
    [Crossref] [Google Scholar]
80. 80.

    Murphy SA, Lynch KG, Oslin D, McKay JR, TenHave T. 2007.. Developing adaptive treatment strategies in substance abuse research. . Drug Alcohol Depend. 88:(Suppl. 2):S24–30
    [Crossref] [Google Scholar]
81. 81.

    Nahum-Shani I, Hekler EB, Spruijt-Metz D. 2015.. Building health behavior models to guide the development of just-in-time adaptive interventions: a pragmatic framework. . Health Psychol. 34:(Suppl.):1209–19
    [Crossref] [Google Scholar]
82. 82.

    Nahum-Shani I, Smith SN, Spring BJ, Collins LM, Witkiewitz K, et al. 2018.. Just-in-time adaptive interventions (JITAIs) in mobile health: key components and design principles for ongoing health behavior support. . Ann. Behav. Med. 52:(6):446–62
    [Crossref] [Google Scholar]
83. 83.

    Natl. Acad. Sci. Eng. Med. 2022.. Methadone Treatment for Opioid Use Disorder: Improving Access Through Regulatory and Legal Change—Proceedings of a Workshop, ed. C Stroud, SM Posey Norris, L Bain . Washington, DC:: Natl. Acad. https://doi.org/10.17226/26635
    [Crossref]
84. 84.

    Naumovska I, Gaba V, Greve HR. 2021.. The diffusion of differences: a review and reorientation of 20 years of diffusion research. . Acad. Manag. Ann. 15:(2):377–405
    [Crossref] [Google Scholar]
85. 85.

    Nesvåg S, McKay JR. 2018.. Feasibility and effects of digital interventions to support people in recovery from substance use disorders: systematic review. . J. Med. Internet Res. 20:(8):e255
    [Crossref] [Google Scholar]
86. 86.

    Nguyen T, Muench U, Andraka-Christou B, Simon K, Bradford WD, Spetz J. 2022.. The association between scope of practice regulations and nurse practitioner prescribing of buprenorphine after the 2016 opioid bill. . Med. Care Res. Rev. 79:(2):290–98
    [Crossref] [Google Scholar]
87. 87.

    O'Grady MA, Lincourt P, Gilmer E, Kwan M, Burke C, et al. 2020.. How are substance use disorder treatment programs adjusting to value-based payment? A statewide qualitative study. . Subst. Abuse 14::1178221820924026
    [Google Scholar]
88. 88.

    Petersen I, van Rensburg A, Kigozi F, Semrau M, Hanlon C, et al. 2019.. Scaling up integrated primary mental health in six low- and middle-income countries: obstacles, synergies and implications for systems reform. . BJPsych Open 5:(5):e69
    [Crossref] [Google Scholar]
89. 89.

    Pincus HA, Fleet A. 2023.. Value-based payment and behavioral health. . JAMA Psychiatry 80:(1):6–8
    [Crossref] [Google Scholar]
90. 90.

    Piper ME, Fiore MC, Smith SS, Fraser D, Bolt DM, et al. 2016.. Identifying effective intervention components for smoking cessation: a factorial screening experiment. . Addiction 111:(1):129–41
    [Crossref] [Google Scholar]
91. 91.

    Raffaelli R. 2015.. Leading and managing change (abridged). Backgr. Note 416021 , Harvard Bus. Sch., Boston:
    [Google Scholar]
92. 92.

    Reay T, Goodrick E, D'Aunno T. 2021.. Health Care Research and Organization Theory. Cambridge, UK:: Cambridge Univ. Press
93. 93.

    Rehm J, Shield KD. 2019.. Global burden of disease and the impact of mental and addictive disorders. . Curr. Psychiatry Rep. 21:(2):10
    [Crossref] [Google Scholar]
94. 94.

    Reif S, Brolin MF, Stewart MT, Fuchs TJ, Speaker E, Mazel SB. 2020.. The Washington State Hub and Spoke Model to increase access to medication treatment for opioid use disorders. . J. Subst. Abuse Treat. 108::33–39
    [Crossref] [Google Scholar]
95. 95.

    Rubin R, Suran M. 2022.. Supervised consumption sites—a tool for reducing risk of overdose deaths and infectious diseases in people who use illicit drugs. . JAMA 327:(16):1532–34
    [Crossref] [Google Scholar]
96. 96.

    SAMHSA (Subst. Abuse Ment. Health Serv. Adm.). 2009.. What are peer recovery support services? HHS Publ. 09-4454, SAMHSA , US Dep. Health Hum. Serv., Rockville, MD:. https://store.samhsa.gov/sites/default/files/sma09-4454.pdf
97. 97.

    SAMHSA (Subst. Abuse Ment. Health Serv. Adm.). 2019.. Use of medication-assisted treatment for opioid use disorder in criminal justice settings. HHS Publ. PEP19-MATUSECJS , SAMHSA, Rockville, MD:. https://store.samhsa.gov/sites/default/files/d7/priv/pep19-matusecjs.pdf
98. 98.

    SAMHSA (Subst. Abuse Ment. Health Serv. Adm.). 2020.. Behavioral health workforce report. HHS Publ. , SAMHSA, Rockville, MD:. https://www.mamh.org/assets/files/behavioral-health-workforce-report.pdf
99. 99.

    SAMHSA (Subst. Abuse Ment. Health Serv. Adm.). 2022.. Key substance use and mental health indicators in the United States: results from the 2021 National Survey on Drug Use and Health. HHS Publ. PEP22-07-01-005, NSDUH Ser. H-57, Cent. Behav. Health Stat. Qual. , SAMHSA, Rockville, MD:. https://www.samhsa.gov/data/report/2021-nsduh-annual-national-report
100. 100.

     Samuels EA, Martin AF. 2022.. Beyond the waiver: multilevel interventions needed to expand buprenorphine treatment. . JAMA Netw. Open 5:(5):e2212425
     [Crossref] [Google Scholar]
101. 101.

     Satinsky EN, Doran K, Felton JW, Kleinman M, Dean D, Magidson JF. 2020.. Adapting a peer recovery coach–delivered behavioral activation intervention for problematic substance use in a medically underserved community in Baltimore City. . PLOS ONE 15:(1):e0228084
     [Crossref] [Google Scholar]
102. 102.

     Schuler MS, Heins SE, Smart R, Griffin BA, Powell D, et al. 2020.. The state of the science in opioid policy research. . Drug Alcohol Depend. 214::108137
     [Crossref] [Google Scholar]
103. 103.

     Soper MH, Matulis R, Menschner C. 2017.. Moving toward value-based payment for Medicaid behavioral health services. Brief, Cent. Health Care Strateg., Washington, DC:. https://www.chcs.org/resource/moving-toward-value-based-payment-medicaid-behavioral-health-services
104. 104.

     Spetz J, Hailer L, Gay C, Tierney M, Schmidt LA, et al. 2022.. Buprenorphine treatment: Advanced practice nurses add capacity. . Health Aff. 41:(9):1231–37
     [Crossref] [Google Scholar]
105. 105.

     Spring B, Pfammatter AF, Marchese SH, Stump T, Pellegrini C, et al. 2020.. A factorial experiment to optimize remotely delivered behavioral treatment for obesity: results of the Opt-IN study. . Obesity 28:(9):1652–62
     [Crossref] [Google Scholar]
106. 106.

     Stensland KD, Sales AE, Damschroder LJ, Skolarus TA. 2022.. Applying implementation frameworks to the clinical trial context. . Implement. Sci. Commun. 3::109
     [Crossref] [Google Scholar]
107. 107.

     Stouten J, Rousseau DM, De Cremer D. 2018.. Successful organizational change: integrating the management practice and scholarly literatures. . Acad. Manag. Ann. 12:(2):752–88
     [Crossref] [Google Scholar]
108. 108.

     Sufrin C, Kramer CT, Terplan M, Fiscella K, Olson S, et al. 2022.. Availability of medications for the treatment of opioid use disorder among pregnant and postpartum individuals in US jails. . JAMA Netw. Open 5:(1):e2144369
     [Crossref] [Google Scholar]
109. 109.

     Tanner AE, Guastaferro KM, Rulison KL, Wyrick DL, Milroy JJ, et al. 2021.. A hybrid evaluation-optimization trial to evaluate an intervention targeting the intersection of alcohol and sex in college students and simultaneously test an additional component aimed at preventing sexual violence. . Ann. Behav. Med. 55:(12):1184–87
     [Crossref] [Google Scholar]
110. 110.

     Teck JTW, Zlatkute G, Perez A, Dritschel H, Ghosh A, et al. 2023.. Key implementation factors in telemedicine-delivered medications for opioid use disorder: a scoping review informed by normalisation process theory. . Lancet Psychiatry 10:(1):50–64
     [Crossref] [Google Scholar]
111. 111.

     Thakrar AP, Alexander GC, Saloner B. 2021.. Trends in buprenorphine use in US jails and prisons from 2016 to 2021. . JAMA Netw. Open 4:(12):e2138807
     [Crossref] [Google Scholar]
112. 112.

     Tofighi B, Abrantes A, Stein MD. 2018.. The role of technology-based interventions for substance use disorders in primary care: a review of the literature. . Med. Clin. N. Am. 102:(4):715–31
     [Crossref] [Google Scholar]
113. 113.

     Torous J, Bucci S, Bell IH, Kessing LV, Faurholt-Jepsen M, et al. 2021.. The growing field of digital psychiatry: current evidence and the future of apps, social media, chatbots, and virtual reality. . World Psychiatry 20:(3):318–35
     [Crossref] [Google Scholar]
114. 114.

     UN. 2021.. World Drug Report 2021. Vienna:: UN Off. Drugs Crime. https://digitallibrary.un.org/record/3931425?ln=en#record-files-collapse-header
115. 115.

     Uwatoko T, Luo Y, Sakata M, Kobayashi D, Sakagami Y, et al. 2018.. Healthy Campus Trial: a multiphase optimization strategy (MOST) fully factorial trial to optimize the smartphone cognitive behavioral therapy (CBT) app for mental health promotion among university students: study protocol for a randomized controlled trial. . Trials 19:(1):353
     [Crossref] [Google Scholar]
116. 116.

     Wang K, Varma DS, Prosperi M. 2018.. A systematic review of the effectiveness of mobile apps for monitoring and management of mental health symptoms or disorders. . J. Psychiatr. Res. 107::73–78
     [Crossref] [Google Scholar]
117. 117.

     Warring W. 2023.. Scaling behavioral health integration in primary care: wading through the complexity to tackle a decades-old challenge. Rep. , Netw. Excel. Health Innov., Boston:. https://www.nehi-us.org/reports/scaling-behavioral-health-integration-in-primary-care-wading-through-the-complexity-to-tackle-a-decades-old-challenge
118. 118.

     Watkins E, Newbold A, Tester-Jones M, Javaid M, Cadman J, et al. 2016.. Implementing multifactorial psychotherapy research in online virtual environments (IMPROVE-2): study protocol for a phase III trial of the MOST randomized component selection method for Internet cognitive-behavioural therapy for depression. . BMC Psychiatry 16::345
     [Crossref] [Google Scholar]
119. 119.

     Weaver A, Lapidos A. 2018.. Mental health interventions with community health workers in the United States: a systematic review. . J. Health Care Poor Underserved 29:(1):159–80
     [Crossref] [Google Scholar]
120. 120.

     Weintraub E, Seneviratne C, Anane J, Coble K, Magidson J, et al. 2021.. Mobile telemedicine for buprenorphine treatment in rural populations with opioid use disorder. . JAMA Netw. Open 4:(8):e2118487
     [Crossref] [Google Scholar]
121. 121.

     Werner RM, Emanuel EJ, Pham HH, Navathe AS. 2021.. The future of value-based payment: a road map to 2030. White Pap. , Leonard Davis Inst. Health Econ., Univ. Pa., Philadelphia:. https://ldi.upenn.edu/wp-content/uploads/2021/07/PennLDI-Future-of-Value-Based-Payment-WhitePaper.pdf
122. 122.

     Westfall JM, Jabbarpour Y, Jetty A, Kuwahara R, Olaisen H, et al. 2022.. The state of integrated primary care and behavioral health in the United States 2022. Rep. , Robert Graham Cent., HealthLandscape, Washington, DC:. https://www.graham-center.org/content/dam/rgc/documents/publications-reports/reports/state-of-integrated-pc-and-bh.pdf
123. 123.

     WHO (World Health Organ.). 2007.. Task Shifting: Rational Redistribution of Tasks Among Health Workforce Teams: Global Recommendations and Guidelines. Geneva:: WHO. http://apps.who.int/iris/bitstream/10665/43821/1/9789241596312_eng.pdf
124. 124.

     WHO (World Health Organ.). 2015.. Integrated care models: an overview. Tech. Rep. , WHO Reg. Off. Eur., Copenhagen:
125. 125.

     WHO (World Health Organ.). 2022.. World mental health report: transforming mental health for all. Rep. , WHO, Geneva:. https://www.who.int/publications/i/item/9789240049338
126. 126.

     Woltmann E, Grogan-Kaylor A, Perron B, Georges H, Kilbourne AM, Bauer MS. 2012.. Comparative effectiveness of collaborative chronic care models for mental health conditions across primary, specialty, and behavioral health care settings: systematic review and meta-analysis. . Am. J. Psychiatry 169:(8):790–804
     [Crossref] [Google Scholar]
127. 127.

     Wyrick DL, Tanner AE, Milroy JJ, Guastaferro K, Bhandari S, et al. 2022.. itMatters: optimization of an online intervention to prevent sexually transmitted infections in college students. . J. Am. Coll. Health 70:(4):1212–22
     [Crossref] [Google Scholar]
128. 128.

     Yoon GH, Levengood TW, Davoust MJ, Ogden SN, Kral AH, et al. 2022.. Implementation and sustainability of safe consumption sites: a qualitative systematic review and thematic synthesis. . Harm Reduct. J. 19::73
     [Crossref] [Google Scholar]
129. 129.

     Yu SWY, Hill C, Ricks ML, Bennet J, Oriol NE. 2017.. The scope and impact of mobile health clinics in the United States: a literature review. . Int. J. Equity Health 16:(1):178
     [Crossref] [Google Scholar]
130. 130.

     Zhou C, Crawford A, Serhal E, Kurdyak P, Sockalingam S. 2016.. The impact of Project ECHO on participant and patient outcomes: a systematic review. . Acad. Med. 91:(10):1439–61
     [Crossref] [Google Scholar]
131. 131.

     Zubatsky M, Edwards TM, Wakabayashi H, Ivbijaro G. 2018.. Integrated behavioural health in primary care across the world: three countries, three perspectives. . Fam. Pract. 35:(6):645–48
     [Crossref] [Google Scholar]